The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated×2•Originally published 21 April 2026•Updated 21 April 2026•

1 min read

Securities Fraud Investigations and Class Action Deadlines Hit MPT, Navan, and Lufax

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Investigation continues into Medical Properties Trust, Inc. (MPT) regarding potential violations of federal securities laws.

2A April 24, 2026 deadline has been set for Navan, Inc. (NAVN) shareholders to join a class action lawsuit related to its IPO.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: The story was expanded to include the new investigation into FS KKR Capital Corp and clarify specific material disclosure dates for TruBridge and OneMain Holdings in early 2026.

Version 1about 1 month ago

What changed: The story was updated to include new legal investigations into Arq, Inc., TruBridge, and OneMain Holdings following recent financial and regulatory triggers.

The scope of legal investigations into federal securities law violations has expanded to include FS KKR Capital Corp (FSK), with Glancy Prongay Wolke & Rotter LLP initiating a probe following material disclosures on February 25, 2026. Significant disclosures were also recorded on March 16, 2026, by TruBridge and OneMain Holdings regarding their ongoing investigations. Arq, Inc. (ARQ) remains under scrutiny for its Q3 2025 results, alongside continued legal pressure on Medical Properties Trust (MPT). Meanwhile, class action deadlines for Navan and Lufax are approaching in April and May 2026, driven by allegations of misleading statements and undisclosed risks. These developments highlight intensifying regulatory risks that could trigger substantial stock volatility and potential settlement costs for the involved entities.